View Older Stories View More Recent Stories

Nov 14, 2018 06:51AM Merck (MRK) Reports Phase 3 KEYNOTE-181 Trial Investigating KEYTRUDA Met a Primary Endpoint of OS in Patients Whose Tumors Express PD-L1
Nov 14, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expre
Nov 13, 2018 04:36PM Merck (MRK) Begins Rolling Submission of Licensure Application for V920 to FDA
Nov 13, 2018 04:35PM Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Nov 12, 2018 06:56AM Merck (MRK) Says FDA Accepted Regulatory Submission for LYNPARZA Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Nov 12, 2018 06:55AM FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
Nov 9, 2018 04:22PM Merck (MRK) Announces FDA Approval of KEYTRUDA for Treatment of Patients with HCC Who Have Been Previously Treated with Sorafenib
Nov 9, 2018 04:21PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
Nov 9, 2018 06:47AM Eisai and Merck (MRK) Announces New Data from Study of LENVIMA and KEYTRUDA Combination in Three Different Tumor Types
Nov 9, 2018 06:45AM New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd An
Nov 7, 2018 06:55AM Merck (MRK) Says Early Phase 1 Data from Oncology Pipeline for Investigational Anti-LAG-3 Therapy and Anti-TIGIT Therapy to Be Presented at SITC
Nov 7, 2018 06:45AM Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting
Nov 5, 2018 10:00AM MilliporeSigma Launches BioContinuum™ Platform for Next-Generation Process Improvements
Nov 1, 2018 07:11AM From pharma to prisons, election-sensitive stocks that could swing
Oct 30, 2018 05:01PM Merck (MRK) Says FDA Approved its KEYTRUDA in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for Patients with NSCLC
Oct 30, 2018 04:09PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Ce
Oct 25, 2018 06:46AM Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization
Oct 25, 2018 06:45AM Merck Announces Third-Quarter 2018 Financial Results
Oct 22, 2018 10:31AM Merck (MRK) Says KEYTRUDA Significantly Improved OS Compared to Standard of Care in Patients with Recurrent or Metastatic Head and Neck Cancer
Oct 22, 2018 10:30AM Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with
Oct 22, 2018 06:48AM Merck (MRK) Says EMA Adopts Positive Opinion for its KEYTRUDA as Adjuvant Therapy in Melanoma
Oct 22, 2018 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma
Oct 22, 2018 06:12AM Merck (MRK) Presents Early Data for Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Oct 22, 2018 05:47AM AstraZeneca (AZN), Merck (MRK) Report Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70%
Oct 21, 2018 10:30AM SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian C
Oct 20, 2018 09:00AM First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Oct 20, 2018 03:15AM Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
Oct 18, 2018 07:01AM Merck (MRK) Reports Significant Improved OS & PFS Data from Pivotal Phase 3 KEYNOTE-426 Trial Investigating KEYTRUDA (pembrolizumab) in Combination with Pfizer’s (PFE) Inlyta (axitinib)
Oct 18, 2018 06:57AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advan
Oct 17, 2018 06:45AM Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer
Oct 16, 2018 06:32AM AstraZeneca (AZN) and Merck (MRK) Announce FDA Grants LYNPARZA Orphan Drug Designation for Pancreatic Cancer
Oct 16, 2018 06:30AM U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer
Oct 10, 2018 06:45AM Merck to Hold Third-Quarter 2018 Sales and Earnings Conference Call on October 25
Oct 9, 2018 06:30AM Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress
Oct 4, 2018 08:00AM MilliporeSigma Opens M Lab™ Collaboration Center in São Paulo, Brazil
Oct 4, 2018 06:45AM Merck (MRK) Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO to Treat HIV
Oct 4, 2018 06:45AM Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Anti
Oct 4, 2018 06:45AM Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Pat
Oct 1, 2018 08:00AM Merck Announces “Safer Childbirth Cities” Initiative, Issues Call to Action to Reverse the Rise in U.S. Maternal Deaths
Sep 26, 2018 06:45AM Merck (MRK) Rescinds Mandatory CEO Retirement Policy
Sep 26, 2018 06:45AM Merck Board Rescinds Mandatory CEO Retirement Policy
Sep 20, 2018 04:31PM Merck (MRK) Receives Positive CHMP Opinion for DELSTRIGO and PIFELTRO in EU for Treatment of HIV-1 Infection
Sep 20, 2018 04:30PM Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection
Sep 20, 2018 08:00AM Merck Publishes Corporate Responsibility Report
Sep 12, 2018 06:48AM Merck (MRK) Granted FDA Priority Review for Application of KEYTRUDA (pembrolizumab) Monotherapy
Sep 12, 2018 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose T
Sep 11, 2018 08:28AM BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Sep 11, 2018 06:46AM Merck's (MRK) ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with HABP or VABP
Sep 11, 2018 06:45AM Merck’s ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or
Sep 10, 2018 06:47AM Merck (MRK) Announces EC Approves its KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for Treatment of Patients with Metastatic Nonsquamous NSCLC
View More Recent Stories View Older Stories